RxDoctor Payments DataLook up a doctor →

Alan Lee, MD

Family Medicine · San Marcos, TXNPI 1336164425

Payments from drug & device makers

$2,856,161in general payments, 2019–2025

Across 290 payments — averaging $9848.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$1.6M
  • Boehringer Ingelheim$855K
  • AstraZeneca$247K
  • Novartis$60K
  • Sanofi US Services Inc.$28K
  • Boehringer Ingelheim International GmbH$27K
  • plus $64K from 15 others
$2,037in research payments, 2019–2025

Across 6 payments — averaging $339.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$2K

What the payments were for

  • Travel & lodging$1,21350%
  • Food & beverage$1,19450%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,856,161 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$228,678
Medicare patients
597
Services billed
5,652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$48,083
JardianceEmpagliflozin24$35,787
Atorvastatin Calcium228$1,921
Levothyroxine Sodium114$1,607
Fluticasone Propionate27$1,074
SynthroidLevothyroxine Sodium11$1,036
Rosuvastatin Calcium88$923
Metformin Hcl59$843
Losartan Potassium70$841
Lisinopril96$700
Gabapentin21$666
Duloxetine Hcl21$640
Pantoprazole Sodium47$583
Metoprolol Succinate30$571
Montelukast Sodium37$529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$269$48,08334 claims
Boehringer IngelheimJardiance$854,823$35,78724 claims
AbbVieSynthroid$125$1,03611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Marcos

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →